SG49650A1 - Agent for improving dementia - Google Patents

Agent for improving dementia

Info

Publication number
SG49650A1
SG49650A1 SG1996002798A SG1996002798A SG49650A1 SG 49650 A1 SG49650 A1 SG 49650A1 SG 1996002798 A SG1996002798 A SG 1996002798A SG 1996002798 A SG1996002798 A SG 1996002798A SG 49650 A1 SG49650 A1 SG 49650A1
Authority
SG
Singapore
Prior art keywords
dementia
disturbances
agent
improving
present
Prior art date
Application number
SG1996002798A
Other languages
English (en)
Inventor
Akira Honma
Eiichi Otomo
Kazuo Hasegawa
Tadashi Shiotani
Yoshiyuki Takasu
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of SG49650A1 publication Critical patent/SG49650A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG1996002798A 1991-05-02 1992-04-30 Agent for improving dementia SG49650A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP22981991 1991-05-02
JP22981891 1991-05-02

Publications (1)

Publication Number Publication Date
SG49650A1 true SG49650A1 (en) 1998-06-15

Family

ID=26529012

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996002798A SG49650A1 (en) 1991-05-02 1992-04-30 Agent for improving dementia

Country Status (22)

Country Link
US (1) US5886023A (sk)
EP (1) EP0515866B1 (sk)
KR (1) KR100310590B1 (sk)
AT (1) ATE203402T1 (sk)
AU (2) AU1595492A (sk)
CA (1) CA2067614C (sk)
CZ (1) CZ281170B6 (sk)
DE (1) DE69231955T2 (sk)
DK (1) DK0515866T3 (sk)
ES (1) ES2160097T3 (sk)
GR (1) GR3036970T3 (sk)
HK (1) HK1002153A1 (sk)
HU (1) HU224689B1 (sk)
IE (1) IE921377A1 (sk)
IL (1) IL101738A (sk)
MX (1) MX9202058A (sk)
NO (1) NO312813B1 (sk)
PT (1) PT515866E (sk)
RU (1) RU2070042C1 (sk)
SG (1) SG49650A1 (sk)
SK (1) SK279285B6 (sk)
TW (1) TW199096B (sk)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1239437A (zh) * 1996-10-01 1999-12-22 第一制药株式会社 线粒体膜稳定剂
CN1264301A (zh) 1997-07-15 2000-08-23 第一制药株式会社 遗忘症的预防、治疗药
WO2000072844A1 (fr) * 1999-05-31 2000-12-07 Daiichi Pharmaceutical Co., Ltd. Inhibiteurs de la mort neuronale
US20040077709A1 (en) * 1999-05-31 2004-04-22 Daiichi Pharmaceutical Co., Ltd. Neuronal death inhibitors
US6376489B1 (en) * 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
US6423739B1 (en) 2000-02-23 2002-07-23 Daiichi Pharmaceutical Co., Ltd. Method for aiding cerebral recovery following neurodegeneration
US6348489B1 (en) * 2000-04-11 2002-02-19 Daiichi Pharmaceutical Co., Ltd. Method of treating traumatic brain injury and other neuronal disorders
JPWO2002053153A1 (ja) * 2000-12-28 2004-04-30 第一製薬株式会社 神経因性疼痛治療及び予防薬
ATE404192T1 (de) * 2001-08-22 2008-08-15 Hamilton Pharmaceuticals Inc Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
US20060241144A1 (en) * 2005-04-20 2006-10-26 Albert Cha Method for treating apathy syndrome
US7972633B2 (en) * 2007-02-07 2011-07-05 Applied Cognitive Sciences, LLC Nutritional supplements for healthy memory and mental function
CN102227217A (zh) * 2008-10-16 2011-10-26 约翰斯.霍普金斯大学 改善认知功能的方法和组合物
EA037187B1 (ru) * 2010-02-09 2021-02-17 Дзе Джонс Хопкинс Юниверсити Способ и композиция для лечения когнитивного расстройства
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
WO2014144801A1 (en) 2013-03-15 2014-09-18 Agenebio Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
US10925834B2 (en) 2015-05-22 2021-02-23 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE864269A (fr) * 1977-03-03 1978-06-16 Parke Davis & Co Nouveaux n-(aminoalkyl substitue)-2-oxo-1-pyrrolidine-acetamides et procedes pour les produire
IT1141287B (it) * 1979-06-13 1986-10-01 Nattermann A & Cie Ammidi di acidi pirrolidin-(2)-on-(1)-ilalchil-carbossilici,procedimento per la loro preparazione e prodotti medicinali che le contengono
US4385053A (en) * 1981-03-11 1983-05-24 Barry Reisberg Treatment for human memory impairment associated with aging
JPH0699307B2 (ja) * 1987-08-20 1994-12-07 キッセイ薬品工業株式会社 抗痴呆剤
IT1231477B (it) * 1989-07-12 1991-12-07 Sigma Tau Ind Farmaceuti (pirrolidin-2-one-1-il) acetammidi quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti

Also Published As

Publication number Publication date
KR920021143A (ko) 1992-12-18
NO312813B1 (no) 2002-07-08
IL101738A0 (en) 1992-12-30
CZ281170B6 (cs) 1996-07-17
IL101738A (en) 1999-01-26
AU3774595A (en) 1996-03-07
HU224689B1 (hu) 2005-12-28
US5886023A (en) 1999-03-23
CS130692A3 (en) 1992-11-18
DK0515866T3 (da) 2001-09-24
ES2160097T3 (es) 2001-11-01
EP0515866A1 (en) 1992-12-02
KR100310590B1 (ko) 2001-12-28
NO921724D0 (no) 1992-04-30
IE921377A1 (en) 1992-11-04
TW199096B (sk) 1993-02-01
GR3036970T3 (en) 2002-01-31
DE69231955D1 (de) 2001-08-30
MX9202058A (es) 1993-03-01
CA2067614A1 (en) 1992-11-03
SK279285B6 (sk) 1998-09-09
DE69231955T2 (de) 2002-04-04
AU697936B2 (en) 1998-10-22
AU1595492A (en) 1992-11-05
CA2067614C (en) 2002-07-30
HU9201477D0 (en) 1992-07-28
HK1002153A1 (en) 1998-07-31
PT515866E (pt) 2001-11-30
ATE203402T1 (de) 2001-08-15
EP0515866B1 (en) 2001-07-25
HUT62790A (en) 1993-06-28
RU2070042C1 (ru) 1996-12-10
NO921724L (no) 1992-11-03

Similar Documents

Publication Publication Date Title
SG49650A1 (en) Agent for improving dementia
DE59109222D1 (de) Verwendung des Wirkstoffs Flupirtin zur Herstellung eines Arzneimittels zur Bekämpfung von Muskelverspannungen
PT1040830E (pt) Medicamento para doencas neurodegenerativas
FI961809A0 (fi) Uudet (R)-5-karbamoyyli-8-fluori-3-N,N-disubstituoitu-amino 3,4-dihydro-2H-1-bentsopyraanit
DE69232323T2 (de) Verwendung von Adenosinantagonisten zur Vorbeugung und Behandlung von Pankreatitis und Ulcera
IT1228288B (it) Composti ad attivita' antiserotoninica
IT1240336B (it) Composizioni farmaceutiche,dietetiche o veterinarie ad attivita' eumetabolica
NO302472B1 (no) Sulfonylureaforbindelse, farmasöytisk formulering og anvendelse derav
DE69024060D1 (de) Osteogenesis-stimulierende mittel.
DK0826373T3 (da) Forebyggende middel mod postoperativ astigmatisme
GB2236528B (en) Aroyl-ureas
ATE81971T1 (de) Synergistische kombination von decarboxylasehemmern und l-dopa-pellets.
DE68906437D1 (de) L-pyroglutamyl-l-cystein-dipeptid mit hoher anti-cataractogener wirkung und dies enthaltende pharmazeutische zusammensetzungen.
CA2154485A1 (en) Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of cns disorders
IL93728A0 (en) Antiviral pharmaceutical compositions containing cyclic amines